Tvardi announces Phase 1 data confirms TTI-109 STAT3 inhibitor efficacy

Tvardi announced positive Phase 1 results for its STAT3 prodrug TTI-109, demonstrating target engagement and significantly improved tolerability compared to the parent compound. The data supports the company's plan to advance TTI-109 into dermatologic and gastrointestinal diseases, subject to funding.